This report provides data related to the safety and effectiveness of repeated time-varying caloric vestibular stimulation (CVS) as a treatment for motor and non-motor features of Parkinson's disease (PD). Forty-six subjects receiving stable anti-Parkinsonian therapy were randomized to active (n ¼ 23) or placebo (n ¼ 23) treatment arms. Subjects self-administered CVS twice-daily over a period of 8 weeks at home via a portable, pre-programmed, solid-state ThermoNeuroModulation (TNM™) device delivering continuallyvarying thermal waveforms through aluminium ear-probes mounted on a wearable headset. Change scores from baseline to end of treatment and to a 1-month follow-up were determined using standardized clinical measures. The data presented here report sample demographics, detailed safety data and the DOI of original article: https://doi.
Data
These data describe the demographic profile of all randomized subjects as well as measures evaluating the safety and effectiveness of the intervention. Fig. 1 shows the number of participants randomized and subsequently entered into the per-protocol, intention-to-treat, and modified intention-to-treat (i.e. participants who completed the first but not second scheduled assessment during treatment) analyses. Fig. 2 shows the thermal profiles of the stimulation waveforms received by active and sham participants and also illustrates an individual undergoing treatment. Table 1 provides the demographic and clinical characteristics of the participants at baseline. Tables 2 and 3 show the intention-to-treat and modified-intention-to-treat statistical outcomes. Table 4 summarizes the adverse events and their likely relation to study participation. Specifications 
Value of the data
The intention-to-treat analyses help clinicians understand the effectiveness of the treatment. The sample demographics help clinicians understand who may benefit from the treatment. The adverse event data help clinicians understand treatment tolerability and how it contrasts with the more commonly applied method of caloric vestibular stimulation which involves chilled water irrigation and is used to diagnose balance disorders and brainstem dysfunction.
Experimental design, materials, and methods
PD patients were recruited from West and East Kent clinical neuroscience services and through the national PD charity Parkinson's UK. Eligibility criteria included the diagnosis of PD by the UK Parkinson's Disease Society Brain Bank Criteria along with reported limitations in activities of daily living. Additionally, patients needed to be receiving stable doses of dopaminergic drugs. Patients with previous exposure to neurostimulation or who were experiencing inner ear pathology were excluded. 
Study design
Eligible subjects completed a 4-week baseline evaluation comprising assessments repeated in the first and fourth week and then were randomized (1:1) to active and placebo treatment groups. Subjects self-administered CVS at home (or if needed, with the help of a caregiver) for 8 weeks. Behavioral assessments were performed midway through the treatment period, at the end of treatment period and then 5 weeks after treatment cessation. All evaluations were conducted by the same blinded clinical researcher in subjects' homes.
Ethical approval was obtained from the East Midlands NHS research ethics committee, and written informed consent was obtained from all subjects at study enrolment. The study was pre-registered at ClinicalTrials.gov as NCT02703844. Table 1 Study demographics and baseline measures. þ indicates non-normal distribution of data; in these cases, the reported values are (median ± range low value, high value). Baseline scores provide the average of the two baseline measures. The VAS provides subjects' perceived effectiveness of their current dopamine replacement therapy (DRT) (1e10).
Intention-To-Treat
Modified Intention-To-Treat Movement Disorder Society Sponsored Unified Parkinson's Disease Rating Scale Part I: nM-EDLþ À 3.0 À1.0 À2.0 À5.5 to 0.0 À3.9 À0.4 À3.5*x À 5.9 to À1.1 Part II: M-EDL À3.4 À0.5 À2.9* À4.9 to À0.9 À3 À0.2 À2.7* À5.3 to À0.7 Part III: Motor exam À8.5 À3.1 À5.3*x À 10.6 to 0.0 À9.2 1.7 À10.9*x À 16.4 to À5. 
Stimulation protocol
For device treatments, subjects were instructed to lie on a 22 -elevated wedge pillow to orient the horizontal semi-circular canal vertically (thereby maximizing vestibular activation). Subjects selfadministered CVS treatments twice daily using the solid-state TNM™ device previously described [2, 3] , and were instructed to separate the two daily treatments by at least 1 hour. Active treatment involved the simultaneous delivery of a time-varying, warm, saw-tooth thermal (37 Ce42 C) stimulus to one ear and a cold saw-tooth thermal (37 Ce17 C) stimulus to the other ear for approximately 19 minutes (Fig. 2) . Every 2 days, the warm and cold waveforms were switched between left and right ears to avoid the possible induction of a long-term, lateralized asymmetry in vestibular function. By slow warming and cooling of inner ear structures, it was possible to avoid vertigo and nausea that can result from chilled water irrigation used in the clinical testing of brainstem function. In the placebo testing condition, subjects underwent the same treatment choreography and experienced the same visual and auditory stimuli associated with running a treatment though no power was delivered to the heating and cooling elements. To maintain treatment blinding, treatment was discussed as brainstem modulation and no reference to the thermal stimulus was made. Subjects were told that they might or might not feel temperature changes in their ears (and that this would not be an indicator of active or placebo treatment; rather, temperature changes are naturally felt by some people and not by others). Subjects were told that they had a 50% likelihood of receiving either placebo or active treatment.
Validated outcome measures
Assessments were performed in the ON medication state (subjects reporting full medication effect against their Parkinsonism) and always timed to occur at the same time relative to the last dose of dopaminergic therapy. Outcome measures included the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) [4] , the Postural Instability and Gait Dysfunction score from the MDS-UPDRS [5] , the Non-Motor Symptom Scale for PD [6] , the Modified Schwab and England Table 4 Adverse events. Abbreviations: Unrelated to device (UR); unlikely related to device (UlR); possibly related to device (PoR); probably related to device (PrR); related to device (R). Activities of Daily Living Scale [7] , the 2 minute walk test [8] , the Timed-Up-and-Go test [9] , the 10 m walk test [10] , the Montreal Cognitive Assessment [11] , the Hospital Anxiety and Depression Scale [12] the EQ-5D-5L [13] , Epworth Sleepiness Scale [14] , the Fatigue Severity Scale [15] , the mental component summary score and physical component summary score of the Short-Form 12 (SF-12) [16] and the Parkinson's Disease Questionnaire-39 index summary score [17] .
Serious adverse events

Statistical analyses
Analysis was conducted on the Intention-to-treat (ITT) dataset at the end of active treatment and at 5-week follow-up and included all randomized subjects (n ¼ 46). Additional analysis was conducted on the modified intention-to-treat (mITT) data which included only those participants who completed the midway-but not end-of-treatment assessment. Results from the per protocol cohort are reported elsewhere [1] . Outcomes were analyzed using analysis of covariance (ANCOVA) to compare the change in the mean response (from the average of week 1 and 4 baseline scores) across treatment groups using an alpha of 0.05. The outcomes were adjusted for baseline symptom severity by including the baseline measure as a covariate. Outcomes with non-normal distributions were analyzed using Wilcoxon Rank Sum tests to compare the median change in response across treatment groups and the Hodges-Lehmann method was used to calculate median difference and confidence intervals. The Last Observation Carried Forward (LOCF) method was used to estimate missing values. The results are presented in Tables 2 and 3 . Analysis was performed using SAS 9.4 (SAS Institute, Cary, NC, USA).
All randomized subjects were monitored for adverse events (AEs). Thirty four AEs were recorded, including 24 AEs in the active arm and 10 AEs in the placebo arm ( Table 4 ). The likely cause of all AEs was determined by independent medical adjudication. All AEs that were deemed as potentially related to device use (n ¼ 5) were non-serious and transient in nature (i.e. ceasing after termination of treatment).
